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a carrier system to deliver clinically relevant disease modifying osteo-
arthritic drugs in a more effective way after intra-articular injection. We
are currently investigating the retention of nanoparticles in the joint
and are developing strategies to target these particles to cartilage.
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MEDINGEL: A CONTROLLED-RELEASE PLATFORM FOR
INTRAARTICULAR DELIVERY OF OSTEOARTHRITIS DRUGS
C. Charles, G. Charles. MedinCell, San Diego, CA, USA
Purpose: Current osteoarthritis treatments have clear delivery limita-
tions and are principally designed to treat symptoms. Drawbacks
include inefﬁcient penetration of drugs into the joint space, systemic
side effects and short duration of action. Drugs administered for
systemic release have poor synovial penetration that is required to
provide relief from OA-related pain and inﬂammation. High plasma
concentrations of many NSAID compounds lead to severe side effects
such as stomach pain and ulcers. And in the case of orally administered
celecoxib, warnings of increased risk for heart attack and stroke have
been issued. MedinCell will present our company's experience in
designing polymer-based delivery technology to circumvent these
problems with the goal of improving osteoarthritis treatments. We will
discuss the use of our MedinGel platform for multi-month local
delivery of small molecules and biologics to help control pain, reduce
inﬂammation and promote cartilage repair. Without controlled release
capability, drugs injected directly into the joint spaces are often cleared
within hours. Yet daily intraarticular injections are untenable, as they
would have to be administered by trained clinicians and would severely
impact the patients’ quality of life. Additionally, a high frequency of
injections into the joint could have increased risk of bacterial infection.
By tailoring formulations to speciﬁc drugs for a range of delivery
durations, MedinCell is conﬁdent that intraarticular formulations can
deliver a sustained therapeutic drug concentration over multiple
months to obviate current concerns and improve both treatment efﬁ-
cacy and patient compliance.
Methods: After evaluation of drug solubility and set up of in vitro-
release assays, a series of sets of formulations evaluating combinations
of polymers at different concentrations were prepared. The MedinGel
matrix is composed of mixtures of drug molecules with solubilized,
bioresorbable polymers. Within minutes after injection through a ﬁne
needle, the aqueous environment of the joint leads to a phase-separa-
tion of the formulated polymers and formation of a three-dimensional
matrix. This resulting semi-solid hydrogel depot entraps and protects
drug molecules within the joint space, and minimizes clearance to the
plasma.
Results: Candidate formulations that provided a range of drug release
rates in vivo were evaluated. The best candidates were then tested by
intraarticular injection. MedinCell has designed intraarticular formu-
lations of OA drug therapies that maintained therapeutic synovial
concentrations for a 3-month duration in animals.
Conclusions: The MedinGel platform enables control over the initial
drug burst characteristics, allowing the remainder of the drug to be
released over a predetermined duration via polymer hydrolysis and
drug diffusion until the depot is completely resorbed. No covalent
modiﬁcation of the active substance is required, which can simplify
regulatory and development pathways. We will present data showing
differential compartmentalization of drug between joint and plasma
when comparing normal injection to MedinGel delivery. Additionally,
MedinCell expects that this technology will provide effective delivery of
disease-modifying caspase inhibitors and proteins (such as BMP7) for
trauma-induced arthritis.
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Purpose: Joint injury is a major risk factor for osteoarthritis (OA); up to
50% of patients develop post-traumatic OA after joint injury. Cartilage
degradation in OA is mediated primarily by proteolytic enzymes thatinclude members of the MMP (matrix metalloproteinase) and ADAMTS
(A Disintegrin And Metalloproteinase with Thrombospondin motifs)
families. There are still no effective treatments to prevent or slow
progressive joint tissue degradation; however, studies in our laboratory
suggest that the transcriptional regulator CITED2, which suppresses
expression of multiple MMPs (-1, -3, -13), plays a chondroprotective
role. In humans and mice, CITED2 expression is lower in OA cartilage
than in healthy controls, suggesting that reduction in CITED2 may
contribute to OA pathogenesis. Suppression of CITED2 by introducing
CITED2 shRNA into joints also upregulatedMMP-13 and ADAMTS-5 and
led to OA-like histologic changes. In contrast, gene transfer of CITED2
into joints of rats with inﬂammatory arthritis limited cartilage matrix
destruction. Therefore, in this study we tested whether CITED2 gene
transfer would similarly prevent OA onset in a mouse model of post-
traumatic OA due to meniscal injury.
Methods: CITED2 gene transfer in vivo and OA induction: Male C57BL/6
mice (8-10-wk old) received intra-articular injections of plasmids
encoding CITED2 cDNA (10 mg/10 mL PBS) in the right knee, followed by
electroporation (225V, 100ms pulse length, 4 pulses each polarity)
every 7 days; left (control) knees received 10 mL PBS followed by elec-
troporation (n¼6). To induce osteoarthritis, destabilization of the
medial meniscus (DMM) was then carried out by transecting the medial
meniscotibial ligament (MMTL) of both limbs. Tissue analyses: Samples
from each knee joint were prepared for histology and for RNA isolation.
Formalin-ﬁxed, decalciﬁed sections were stained overnight at 4C with
anti-CITED2, anti-MMP-13, anti-ADAMTS-5 or irrelevant isotype-
matched antibody controls, followed by anti-rabbit or anti-mouse
secondary antibody and visualized with DAB chromagen. Safranin O-
Fast green staining was used to detect proteoglycans. Expression of
CITED2, MMP-13, and ADAMTS5 in articular cartilage was assessed by
SYBR green real-time qPCR.
Results: Four weeks after DMM, joints receiving CITED2 by gene
transfer (DMM+CITED2) showed elevated mRNA levels of CITED2 and
reduced mRNA levels of MMP-13 and ADAMTS5 compared to DMM
joints receiving PBS (DMM+PBS) (Fig 1). Histologically, DMM+CITED2
mice exhibited reduced cartilage degradation (OARSI score 0.33  0.28)
compared to DMM+PBS controls (OARSI score: 1.33  0.28) (Fig 2).
Immunohistochemistry showed that DMM+CITED2 mice had an
increased number of chondrocytes expressing CITED2 and fewer
chondrocytes expressing MMP-13 and ADAMTS-5 than DMM+PBS
controls (Fig 3).
Conclusions: Our previous studies suggested that reduced CITED2
expression in cartilage contributes to OA pathogenesis. Our present
results support the hypothesis that restoration of CITED2 in OA joints by
gene transfer would limit disease progression and speciﬁcally implicate
MMP-13 and ADAMTS5 as targets for CITED2 downregulation. This
suggests that increasing CITED2 expression in articular cartilage may be
a novel chondroprotective strategy for the treatment of OA.Ă
